Here are four things to know:
1. Nine analysts rated the stock “buy,” 10 analysts rated it “outperform” and 10 analysts rated it “hold.”
2. Analysts gave a consensus estimate of $1.93 share, which compares with $1.58 the same quarter last year.
3. Wall Street analysts predict Zimmer Biomet will see an annual growth of about 10.69 percent over the next five years.
4. Some analysts predict the 12-month average price target will hit $150, while others predict it will reach $120.71.
More articles on devices:
Orthofix upgraded to ‘strong buy’ rating — 5 insights
MIS Pedicle Screw Systems receive additional clearance for larger diameter pedicle screws
5th Neuro-Spinal Scaffold for spinal cord injury shows improvement at 6 months: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
